Last reviewed · How we verify

NCT06763926: INFORM

Intranasal Nafarelin For Triggering Oocyte Maturation

Not yet recruiting Phase 4 Last updated 26 February 2025
What this trial tests

Phase 4 trial testing Subcutaneous Triptorelin in Fertility Disorders in 134 participants. Not yet recruiting.

Timeline
15 March 2025
Primary endpoint
15 January 2026
15 January 2026

Quick facts

Lead sponsorFundacion Dexeus
PhasePhase 4
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment134
Start date15 March 2025
Primary completion15 January 2026
Estimated completion15 January 2026
Sites4 locations across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Fundacion Dexeus — full company profile →

Who can join

Adults 18 to 35, female only, with Fertility Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a non-inferiority randomised, controlled clinical trial comparing subcutaneous triptorelin to intranasal nafarelin for the final maturation of oocytes in oocyte donors undergoing ovarian stimulation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Fertility Disorders

Currently open trials in the same condition.

Other Fundacion Dexeus trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06763926.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing